Preinterventional pan-immune-inflammation value as a tool to predict postcontrast acute kidney injury among acute coronary syndrome patients implanted drug-eluting stents: a retrospective observational study

Basit Öğe Kaydı
dc.contributor.authorKurtul, Alparslan
dc.contributor.authorGok, Murat
dc.date.accessioned2024-09-18T20:54:24Z
dc.date.available2024-09-18T20:54:24Z
dc.date.issued2024
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractWe evaluated the value of pan-immune-inflammation value (PIV) in predicting the risk for postcontrast acute kidney injury (PCAKI), an important complication following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients. Medical records of 839 ACS patients underwent PCI between June 2019 and December 2022 were retrospectively analyzed. Patients were divided into two groups: PCAKI (-) and PCAKI (+). PCAKI was defined as a >= 0.5 mg/dL and/or a >= 25% increase in serum creatinine within 72 h after PCI. The PIV was computed as [neutrophils x platelets x monocytes]divided by lymphocytes. The mean age was 60.7 +/- 12.9 years. PCAKI was detected in 105 (12.51%) patients. PIV was higher in the PCAKI (+) group compared to PCAKI (-) group (median 1150, interquartile range [IQR] 663-2021 vs median 366, IQR 238-527, p < 0.001). Receiver operating characteristic curve analysis showed that the best cutoff of PIV for predicting PCAKI was 576 with 81% sensitivity and 80% specificity. PIV was superior to neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for the prediction of PCAKI (area under curve:0.894, 0.849 and 0.817, respectively, p < 0.001 for all). A high PIV was independently correlated with PCAKI (<= 576 vs. >576, odds ratio [OR] 12.484, 95%confidence interval [CI] 4.853-32.118, p < 0.001) together with older age (OR 1.058, p = 0.009), female gender (OR 4.374, p = 0.005), active smoking (OR 0.193, p = 0.012), left ventricular ejection fraction (OR 0.954, p = 0.021), creatinine (OR 10.120, p < 0.001), hemoglobin (OR 0.759, p = 0.019) and c-reactive protein (OR 1.121, p = 0.002). In conclusion, a high PIV seems to be an easily assessable tool that can be used in clinical practice for predicting the risk of PCAKI in ACS patients implanted drug-eluting stents.en_US
dc.identifier.doi10.1080/00365513.2024.2330904
dc.identifier.endpage103en_US
dc.identifier.issn0036-5513
dc.identifier.issn1502-7686
dc.identifier.issue2en_US
dc.identifier.pmid38506475en_US
dc.identifier.scopus2-s2.0-85188590957en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage97en_US
dc.identifier.urihttps://doi.org/10.1080/00365513.2024.2330904
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11790
dc.identifier.volume84en_US
dc.identifier.wosWOS:001189736300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofScandinavian Journal of Clinical & Laboratory Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPostcontrast acute kidney injuryen_US
dc.subjectpan-immune-inflammation valueen_US
dc.subjectacute coronary syndromeen_US
dc.subjectpercutaneous coronary interventionen_US
dc.titlePreinterventional pan-immune-inflammation value as a tool to predict postcontrast acute kidney injury among acute coronary syndrome patients implanted drug-eluting stents: a retrospective observational studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu